$11.00
−8.33%Price chart
Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14Sep 17
Key dataSep 17, 2026
Open$11.49
From 52W high−63.32%
Volume1503.00
Market cap$1.26B
P/E (TTM)—
P/S (TTM)176.7x
Div yield—
Key dataSep 17, 2026
Open
$11.49
From 52W high
−63.32%
Volume
1503.00
Market cap
$1.26B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
P/E (TTM)
—
RSI (14)
13.9
MomentumView details →
1D Return
−8.33%
YTD Return
−52.17%
SummaryUpdated Jun 1, 2026
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands. The company went public in February 2021 and focuses on developing innovative treatments for metabolic diseases, particularly cardiovascular conditions related to cholesterol management. NewAmsterdam's primary focus is advancing its lead drug candidate through clinical trials to address unmet medical needs in cholesterol treatment and cardiovascular disease prevention.
Similar companies
Latest newsMore news →
NewAmsterdam Pharma CEO Davidson acquired 10,000 shares of the company for about $226,500 on September 14, per an SEC filing.4d agoNewAmsterdam Pharma Co N.V. appointed Robert W. Gunning as principal accounting officer, Vice President and Controller, effective August 10, 2026, succeeding Louise Kooij who will depart on August 31, 2026.37d agoNewAmsterdam Pharma Co N.V. elected John W. Smither and Janneke van der Kamp as non-executive directors, effective June 2, 2026.109d ago